GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius Medical Care AG (NYSE:FMS) » Definitions » 14-Day RSI

Fresenius Medical Care AG (Fresenius Medical Care AG) 14-Day RSI

: 44.81 (As of Today)
View and export this data going back to 1996. Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-16), Fresenius Medical Care AG's 14-Day RSI is 44.81.

The industry rank for Fresenius Medical Care AG's 14-Day RSI or its related term are showing as below:

FMS's 14-Day RSI is ranked worse than
52.33% of 688 companies
in the Healthcare Providers & Services industry
Industry Median: 44.285 vs FMS: 44.81

Competitive Comparison

For the Medical Care Facilities subindustry, Fresenius Medical Care AG's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresenius Medical Care AG 14-Day RSI Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Fresenius Medical Care AG's 14-Day RSI falls into.



Fresenius Medical Care AG  (NYSE:FMS) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresenius Medical Care AG  (NYSE:FMS) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Fresenius Medical Care AG 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Fresenius Medical Care AG's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresenius Medical Care AG (Fresenius Medical Care AG) Business Description

Address
Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.
Executives
Helen Pring Giza Board of Directors